Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437335 | 0.85 | SIGMAR1 (0.58) | DRD2PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL6374865 | 0.85 | PARP1 (0.48) | DRD2PPARGPPARASIGMAR1 | |
| SCHEMBL6367176 | 0.83 | DRD2 (0.61) | DRD2SIGMAR1CYP2D6THPO | |
| SCHEMBL5535410 | 0.82 | SIGMAR1 (0.46) | DRD2PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL6373489 | 0.82 | SIGMAR1 (0.55) | DRD2SIGMAR1 | |
| SCHEMBL5535869 | 0.82 | PPARG (0.48) | PPARGPPARAS1PR1S1PR3SIGMAR1 | |
| SCHEMBL5544450 | 0.81 | SIGMAR1 (0.48) | DRD2PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL6373296 | 0.81 | DRD2 (0.61) | DRD2SIGMAR1 | |
| SCHEMBL6368144 | 0.81 | SIGMAR1 (0.55) | DRD2S1PR1S1PR3SIGMAR1 | |
| SCHEMBL6374778 | 0.80 | SIGMAR1 (0.58) | DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | DRD2 1026/4885PPARG 3444/4885PPARA 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.